Selank
Synthetic analog of tuftsin investigated for calming effects without sedation in high-cognitive-load states.
This compound was removed from FDA Category 2 in 2026, but final action on the 503A compounding list is still pending. Allora does not currently dispense it — join the waitlist and we will notify you if it becomes available through our licensed pharmacy partners.
Mechanism of action
How Selank works
Modulates GABAergic and serotonergic signaling and influences enkephalin metabolism, with effects on anxiety and stress response.
Areas of study
What Selank is studied for
- check
Anxiety management without sedation
- check
Cognitive performance under stress
Considerations
Important things your physician will discuss
This is general clinical context — not medical advice. Your evaluation determines whether Selank is appropriate for you.
- info
Removed from FDA Category 2 in 2026; final action on the 503A compounding list is pending — currently offered as educational information and waitlist only
- info
Not FDA approved in the United States
- info
Should be coordinated with any existing psychiatric care
Related peptides
More from the Cognitive category
This compound is pending FDA compounding review.
We don't dispense it today. Join the waitlist and we'll notify you if it becomes available through our licensed pharmacy partners.